Related Experiment Video
Updated: Jul 5, 2025

11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.0K
Characterizing Immune Infiltration in Esthesioneuroblastoma Subtypes Through Gene Expression Deconvolution.
Sai Batchu1, Amarbir S Gill2, Michael Karsy3
1Cooper Medical School at Rowan University, Camden, New Jersey, USA.
World Neurosurgery
|January 21, 2024
Summary
Esthesioneuroblastoma subtypes show distinct immune cell profiles, with basal ENB having more activated CD4 memory T cells. These differences may influence patient outcomes and guide future immunotherapies.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Esthesioneuroblastoma (ENB) is a rare olfactory mucosa cancer with basal and neural genomic subtypes.
- The basal subtype is linked to poorer survival and higher tumor-infiltrating immune cells (TIICs).
- The immune microenvironment differences between ENB subtypes are not well understood.
Purpose of the Study:
- To characterize and compare the immune microenvironment of basal and neural Esthesioneuroblastoma subtypes.
- To identify differences in tumor-infiltrating immune cells (TIICs) between ENB subtypes using transcriptomic data.
Main Methods:
- Utilized the CIBERSORTx machine learning algorithm on RNA sequencing data from 18 ENB cases.
- Characterized 22 distinct immune cell populations to analyze their proportions in basal versus neural ENB.
- Correlated immune cell profiles with clinical and genomic features.
Main Results:
- No significant differences in age, grade, or PD-L1 expression were observed between basal and neural ENB subtypes.
- M2 macrophages, naïve B cells, and CD4 memory resting T cells were the most abundant immune cells overall.
- Activated CD4 memory T cells were elevated in basal ENB, while resting dendritic cells were increased in neural ENB, suggesting distinct immune profiles.
Conclusions:
- Basal and neural ENB subtypes exhibit unique tumor-infiltrating immune cell (TIIC) compositions.
- These immunoprofile differences may contribute to the varying clinical outcomes of ENB subtypes.
- Findings support further research into immunomodulatory strategies for Esthesioneuroblastoma treatment.

